Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

DAPA-MEMRI retssagen (DAPA-MEMRI)

18. september 2026 opdateret af: University of Edinburgh

En observationel tværsnitsundersøgelse og en dobbeltblind placebokontrolleret randomiseret kontrolleret undersøgelse for at vurdere virkningen af ​​Dapagliflozin på myokardiecalciumhåndtering hos patienter med hjertesvigt- DAPA-MEMRI-forsøget.

Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle including scarring and thickening. Contraction of the heart involves movement of calcium across the heart muscle and disruption of this process is an early change seen in heart failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to benefit patients with heart failure but the mechanisms of benefit are unknown.

Our hypothesis is that calcium handling is altered in patients with either type 2 diabetes mellitus (T2DM) or heart failure and that SGLT2 inhibitors can improve this in heart failure irrespective of the presence of T2DM.

Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function by using a new contrast 'dye' containing manganese that has shown advantages over traditional contrast. We plan to further test this new dye as it has the potential to track and quantify improvements in heart function over time and detect changes in calcium handling in the heart muscle, making it an ideal measure to identify the mechanisms of benefit from SGLT2 inhibitor therapy.

The study population will comprise patients with heart failure with and without type 2 diabetes, patients with type 2 diabetes without heart failure and healthy volunteers. Baseline comparisons will be made between the four groups before progressing to the randomised controlled trial with heart failure patients only. Patients will have a clinical assessment and blood tests, electrocardiogram, echocardiogram and MRI of the heart at each visit.

If successful, this study will give us significant insights into mechanisms of action of SGLT2 inhibitors in heart failure and will enable us to tailor specific treatments in heart failure patients.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The study is designed to investigate the myocardial calcium handling in patients with heart failure with or without type 2 diabetes mellitus and if Dapagliflozin (study drug) improves the myocardial calcium handling in patients with heart failure and diabetes mellitus.

We propose to conduct this study in two parts.

  1. OBSERVATIONAL CROSS-SECTIONAL STUDY

    An observational cross-sectional study will be undertaken to compare myocardial calcium in patients with diabetes mellitus and normal left ventricular ejection fraction (n=20), patients with heart failure in the absence of diabetes mellitus (n=60), and patients with both diabetes mellitus and heart failure (n=60). They will be compared with healthy volunteers (n=20).

    There will be an initial meeting, where informed consent will be documented and a medical assessment including blood tests will be undertaken as well as an echocardiogram will be performed. Healthy volunteers will only undergo Manganese enhanced cardiac MRI scan. The other cohorts will undergo a gadolinium enhanced cardiac MRI scan on their first visit. On a subsequent visit, they will undergo 1 cardiac Manganese enhanced Manganese MRI scan (MEMRI) which lasts 45-60 minutes. Participants will be monitored with blood pressure and ECG monitoring throughout the MEMRI scan. Patients will be offered an anti-sickness medication if required following the MEMRI scan.

  2. RANDOMISED CONTROLLED TRIAL

We will undertake a randomised double-blind placebo controlled trial of patients with heart failure with (n=60) and without (n=60) type 2 diabetes mellitus. These participants would have been recruited as part of the observational study as described above from out-patient clinics at the Edinburgh Heart Centre. If all eligibility criteria are met, patients will be randomised to receive treatment with either Dapagliflozin 10 mg, or matched placebo, once daily for 6 months at a ratio of 1:1. Detailed clinical assessment including history and examination, blood sampling, electrocardiogram, echocardiogram and cardiac MRI will be collected at baseline, 1 and 6 months.

There will also be a 3 month safety visit after randomisation to record any adverse events.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

81

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Patients with heart failure (with or without type 2 diabetes mellitus)

  • Aged over 18 years
  • Diagnosis of symptomatic reduced ejection fraction heart failure for at least 2 months
  • Left ventricular ejection fraction ≤40%
  • Elevated N-terminal pro B-type natriuretic peptide (>125 pg/mL)
  • Clinical diagnosis of type 2 diabetes mellitus for 50% of patient population - on stable therapy for at least 12 months or more.

Patients with Type 2 Diabetes Mellitus and no heart failure

  • Aged over 18 years

  • Clinical diagnosis of type 2 diabetes mellitus (diagnosed by either HbA1c of 48mmol/mol (6.5%) or greater or fasting plasma glucose level of 7mmol/L or greater at the time of diagnosis)

    - on stable therapy for at least 12 months or more.

  • Normal left ventricular systolic ejection fraction

Healthy Volunteers

  • Aged over 18 years
  • Normal left ventricular ejection fraction and glycaemia
  • No clinically significant co-morbid conditions

Exclusion Criteria:

Patients with heart failure (with or without type 2 diabetes mellitus)

  • Receiving an SGLT2 inhibitor within 8 weeks of enrolment
  • Previous intolerance of, or contraindication to, an SGLT2 inhibitor
  • Standard magnetic resonance imaging safety exclusions
  • Severe renal impairment (eGFR <30millilitre/min. 1.73m2)
  • Type 1 diabetes mellitus
  • Symptomatic hypotension or systolic blood pressure <95 mmHg
  • Recent (within 12 weeks) hospitalisation for heart failure, acute cardiovascular event (such as myocardial infarction or stroke) or coronary re-vascularisation.
  • 2nd or 3rd degree atrioventricular block Atrial fibrillation or flutter with poor ventricular rate control (>100 /min)
  • Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
  • New York Heart Association grade IV heart failure
  • Obstructive liver function testing abnormalities
  • Concomitant digoxin, diltiazem or verapamil therapy.

Patients with type 2 diabetes mellitus and no heart failure

  • Other major clinically significant co-morbid conditions
  • History of ischaemic heart disease or present history suggestive of probable clinically significant underlying ischaemic heart disease
  • Standard magnetic resonance imaging safety exclusions
  • Moderate or severe renal impairment (eGFR <45 mL/min. 1.73m2)
  • Receiving a SGLT2 inhibitor at any time
  • Symptomatic hypotension or systolic blood pressure <95 mmHg
  • Abnormal electrocardiogram
  • Clinically significant abnormalities of clinical haematology or biochemistry measurements.

Healthy Volunteers

  • Major or clinically significant cardiovascular disease
  • Diabetes mellitus
  • Receiving an SGLT2 inhibitor at any time
  • Standard magnetic resonance imaging safety exclusions
  • Moderate or severe renal impairment (eGFR <45 mL/min. 1.73m2)
  • Symptomatic hypotension or systolic blood pressure <95 mmHg
  • Abnormal electrocardiogram
  • Clinically significant abnormalities of clinical haematology or biochemistry measurements.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Patients with heart failure without type 2 diabetes

60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.

Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Andet: Patients with heart failure with type 2 diabetes

60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.

Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Ændringshastighed i myokardie T1-værdier med manganforstærket hjerte-MRI
Tidsramme: 6 måneder
6 måneder

Sekundære resultatmål

Resultatmål
Tidsramme
Venstre ventrikulær ejektionsfraktion målt i procent på hjerte-MR
Tidsramme: 6 måneder
6 måneder
Venstre ventrikelmasse målt i gram på hjerte-MR
Tidsramme: 6 måneder
6 måneder
Hjertebiomarkører som N-terminal pro B-type natriuretisk peptid i nanogram per liter
Tidsramme: 6 måneder
6 måneder
Markører for diabeteskontrol inklusive glukose i millimol pr. liter
Tidsramme: 6 måneder
6 måneder
Kliniske mål såsom hjertefrekvens i slag i minuttet
Tidsramme: 6 måneder
6 måneder
Ekstracellulært volumen i procent ifølge hjerte-MR-målinger
Tidsramme: 6 måneder
6 måneder
Global langsgående belastning i procent som beregnet på hjerte-MRI
Tidsramme: 6 måneder
6 måneder
Kliniske mål såsom kropsvægt i kilogram
Tidsramme: 6 måneder
6 måneder
Kliniske mål såsom blodtryk i millimeter kviksølv
Tidsramme: 6 måneder
6 måneder
Hjertebiomarkører som højfølsomt hjertetroponin I i nanogram pr. liter
Tidsramme: 6 måneder
6 måneder
Mål for glukosekontrol som glykeret hæmoglobin (HbA1c) i millimol pr.
Tidsramme: 6 måneder
6 måneder

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. august 2020

Primær færdiggørelse (Faktiske)

1. januar 2025

Studieafslutning (Faktiske)

1. januar 2025

Datoer for studieregistrering

Først indsendt

14. august 2020

Først indsendt, der opfyldte QC-kriterier

12. oktober 2020

Først opslået (Faktiske)

19. oktober 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • AC20006

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .